Vivos Therapeutics (VVOS) Gross Margin (2020 - 2025)
Vivos Therapeutics (VVOS) has disclosed Gross Margin for 6 consecutive years, with 58.01% as the latest value for Q3 2025.
- On a quarterly basis, Gross Margin fell 245.0% to 58.01% in Q3 2025 year-over-year; TTM through Sep 2025 was 55.73%, a 607.0% decrease, with the full-year FY2024 number at 60.0%, up 7.0% from a year prior.
- Gross Margin was 58.01% for Q3 2025 at Vivos Therapeutics, up from 55.24% in the prior quarter.
- In the past five years, Gross Margin ranged from a high of 80.59% in Q2 2021 to a low of 50.03% in Q1 2025.
- A 5-year average of 62.76% and a median of 60.59% in 2023 define the central range for Gross Margin.
- Peak YoY movement for Gross Margin: crashed -1873bps in 2022, then skyrocketed 757bps in 2024.
- Vivos Therapeutics' Gross Margin stood at 70.7% in 2021, then fell by -15bps to 60.35% in 2022, then rose by 7bps to 64.32% in 2023, then dropped by -12bps to 56.71% in 2024, then grew by 2bps to 58.01% in 2025.
- Per Business Quant, the three most recent readings for VVOS's Gross Margin are 58.01% (Q3 2025), 55.24% (Q2 2025), and 50.03% (Q1 2025).